PRESS RELEASE FEBRUARY 23, 2024
APPROVAL OF ALL RESOLUTIONS PUT TO THE VOTE OF THE GENERAL MEETING OF HOLDERS OF CONVERTIBLE BONDS ISSUED IN APRIL 2021
Villejuif, France, February 23, 2024 at 7:45 p.m. CET – PREDILIFE
(Euronext Growth: ALPRE FR0010169920) (the “
Company
), specialist in artificial intelligence applied to predictive medicine for a personalized approach, announces that all of the resolutions necessary to modify the terms and conditions of bonds convertible or exchangeable into new or existing shares (the “
OCEANE 2021
“) issued as part of the public offering open from March 19, 2021 to April 16, 2021, were approved as part of the 2021 general meeting of OCEANE holders held today (the ”
Assembly
“).
Stéphane Ragusa, Chairman and CEO of Predilife, declares: “
I thank the bondholders for their broad approval of the proposed resolutions which illustrates their confidence in the future of predictive medicine. The extension of these OCEANEs will make it possible to encourage the development of activity with companies in partnership with insurance companies and brokers. It will also make it possible to promote our unique assets in terms of breast cancer.
“.
Results of votes from the 2021 general meeting of OCEANE holders
The Meeting meeting today approved all the resolutions relating to the modifications to the terms and conditions of the 2021 OCEANEs, relating in particular to (i) the postponement of the maturity of the 2021 OCEANEs to April 2029, (ii) the increase of the annual interest rate from 7% to 8.5% from April 30, 2024, and (iii) the modification of the conditions of reimbursement of the OCEANE 2021 at maturity.
All resolutions were adopted by a majority of more than 75%. 300 2021 OCEANEs were registered out of a total of 510 2021 OCEANEs in circulation, representing a quorum of 58.82% on first call.
The Company reminds that the entry into force of the modifications approved by the Meeting is subject to the agreement of the shareholders who will meet in a general meeting no later than April 29, 2024. More details on the convening of the shareholders of the Company will be available later.
About Predilife
PREDILIFE is a pioneering company in the design and development of prediction tests intended to prevent major diseases. It uses artificial intelligence methods applied to clinical and genetic medical data within a secure legal framework. Predicting these individual risks makes it possible to propose a personalized monitoring protocol and earlier identification of pathologies.
To find out more: https://www.predilife.com
Contacts
PREDILIFE Investor Relations
Stéphane Ragusa
Chairman and CEO
CAPVALUE Press Relations
01 80 81 50 00
This publication has the “🔒 Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
lWlrZMhqlJyclp2ak5uXa5dsZ2ZoxJXHbGObmGWdl5ecmm1olmySbZfLZnFlmGhn
– To control this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Other press releases
Full and original press release in PDF format:
https://www.actusnews.com/news/84331-predilife-communique-de-presse-compte-rendu-de-l_assemblee-generale-des-porteurs-d_oceane-2021-23.02.24.pdf
© Copyright Actusnews Wire
Receive future company press releases free of charge by email by subscribing to www.actusnews.com